Is Risk Stratification for Bleeding and Ischemic Events Still Useful When De-Escalating to Ticagrelor Monotherapy?

J Am Coll Cardiol. 2023 Aug 22;82(8):701-703. doi: 10.1016/j.jacc.2023.06.010.

Authors

Puja B Parikh¹, Tullio Palmerini²

Affiliations

¹ Division of Cardiovascular Medicine, Department of Medicine, Stony Brook University Renaissance School of Medicine, Stony Brook, New York, USA. Electronic address: puja.parikh@stonybrookmedicine.edu.
² Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Cardiac Thoracic and Vascular Department, Alma Mater Studiorum, Universita di Bologna, Bologna, Italy.

PMID: 37587581
DOI: 10.1016/j.jacc.2023.06.010

No abstract available

Keywords: aspirin; bleeding; dual antiplatelet therapy; monotherapy; risk; ticagrelor.

Publication types

Editorial
Comment

MeSH terms

Hemorrhage* / chemically induced
Humans
Risk Assessment
Ticagrelor / therapeutic use

Substances

Ticagrelor